These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33642128)

  • 21. Exercise Training Improves Tumor Control by Increasing CD8
    Gomes-Santos IL; Amoozgar Z; Kumar AS; Ho WW; Roh K; Talele NP; Curtis H; Kawaguchi K; Jain RK; Fukumura D
    Cancer Immunol Res; 2021 Jul; 9(7):765-778. PubMed ID: 33839688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abscopal Effect of Radiotherapy Enhanced with Immune Checkpoint Inhibitors of Triple Negative Breast Cancer in 4T1 Mammary Carcinoma Model.
    Song HN; Jin H; Kim JH; Ha IB; Kang KM; Choi HS; Jeong HJ; Kim MY; Kim HJ; Jeong BK
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
    Cao L; Dai C; Qin R; Guo Y; Liu J
    Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624
    [No Abstract]   [Full Text] [Related]  

  • 27. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
    Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
    Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8
    Shan CK; Du YB; Zhai XT; Wang YX; Li Y; Gong JH; Ge ZJ; Liu XJ; Zhen YS
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):425-436. PubMed ID: 33388950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
    Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
    Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
    Chen JS; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Sci Rep; 2022 Jan; 12(1):1100. PubMed ID: 35058524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models.
    Fukushima H; Furusawa A; Takao S; Thankarajan E; Luciano MP; Usama SM; Kano M; Okuyama S; Yamamoto H; Suzuki M; Kano M; Choyke PL; Schnermann MJ; Kobayashi H
    Oncoimmunology; 2024; 13(1):2370544. PubMed ID: 38915782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
    Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
    Fabian KP; Padget MR; Fujii R; Schlom J; Hodge JW
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
    Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
    J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
    Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
    Front Immunol; 2019; 10():1939. PubMed ID: 31475002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8
    Song F; Hu B; Liang XL; Cheng JW; Wang CG; Wang PX; Wang TL; Tang PJ; Sun HX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Clin Transl Med; 2024 Aug; 14(8):e1738. PubMed ID: 39095323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.